TW270115B - - Google Patents

Info

Publication number
TW270115B
TW270115B TW082103682A TW82103682A TW270115B TW 270115 B TW270115 B TW 270115B TW 082103682 A TW082103682 A TW 082103682A TW 82103682 A TW82103682 A TW 82103682A TW 270115 B TW270115 B TW 270115B
Authority
TW
Taiwan
Prior art keywords
pyridazo
pyrazolo
pyridazine
diazepine
enkephalinase
Prior art date
Application number
TW082103682A
Other languages
English (en)
Chinese (zh)
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Application granted granted Critical
Publication of TW270115B publication Critical patent/TW270115B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
TW082103682A 1992-05-15 1993-05-11 TW270115B (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88496392A 1992-05-15 1992-05-15
US4000393A 1993-04-09 1993-04-09

Publications (1)

Publication Number Publication Date
TW270115B true TW270115B (enExample) 1996-02-11

Family

ID=26716641

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082103682A TW270115B (enExample) 1992-05-15 1993-05-11

Country Status (19)

Country Link
US (1) US5366973A (enExample)
EP (1) EP0640086B1 (enExample)
JP (1) JP3360079B2 (enExample)
KR (1) KR100281450B1 (enExample)
AT (1) ATE182892T1 (enExample)
AU (1) AU669364B2 (enExample)
CA (1) CA2133963C (enExample)
DE (1) DE69325904T2 (enExample)
DK (1) DK0640086T3 (enExample)
ES (1) ES2138622T3 (enExample)
FI (1) FI108230B (enExample)
GR (1) GR3031287T3 (enExample)
HU (1) HU223663B1 (enExample)
IL (1) IL105680A (enExample)
MX (1) MX9302824A (enExample)
NO (1) NO302573B1 (enExample)
NZ (1) NZ251930A (enExample)
TW (1) TW270115B (enExample)
WO (1) WO1993023403A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
US5654294A (en) * 1993-05-13 1997-08-05 Bristol-Myers Squibb Spiro lactam dual action inhibitors
EP0671172A4 (en) * 1993-06-11 1998-09-02 Eisai Co Ltd AMINO ACID DERIVATIVE.
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
CA2183314C (en) * 1994-02-14 1999-08-31 Gary A. Flynn Novel 2-substituted indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
DK0745081T3 (da) * 1994-02-14 2002-05-21 Merrell Pharma Inc Indan-2-mercaptoacetylamiddisulfidderivater, der er anvendelige som enkephalinase-inhibitorer
FI963169A0 (fi) * 1994-02-14 1996-08-13 Merrell Pharma Inc Enkefalinaasin ja ACE:n inhibittoreina käyttökelpoisia uusia merkaptoasetyyliamido-1,3,4,5-tetrahydrobents/c/-atsepin-3-onidisulfidijohdannaisia
NZ282568A (en) * 1994-03-24 1997-07-27 Merrell Pharma Inc Use of condensed aminoacetylmercaptobenzazepines in treating elevated cholesterol levels, atherosclerosis, and hypotriglyceridemia
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US6699869B1 (en) 1995-03-24 2004-03-02 Myriad Genetics Inc. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US6020331A (en) 1995-03-24 2000-02-01 Molecumetics, Ltd. β-sheet mimetics and use thereof as protease inhibitors
US6245764B1 (en) 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US5877313A (en) * 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US6117896A (en) 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
JP2002503674A (ja) * 1998-02-12 2002-02-05 モレキュメティックス リミテッド βシート模倣物およびその使用に関する方法
IT1298268B1 (it) * 1998-02-18 1999-12-20 Zambon Spa Procedimento per la preparazione dell'acido (s)-2-bromo-3-fenil- propionico
FR2777889B1 (fr) * 1998-04-27 2004-07-09 Hoechst Marion Roussel Inc Nouveaux derives de l'acide octahydro-6,10-dioxo-6h- pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de composes therapeutiquement actifs
EP1087775B1 (en) 1998-06-17 2005-08-17 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
US6177565B1 (en) 1998-08-19 2001-01-23 Vertex Pharmaceuticals Inc. Process for synthesizing piperazic acid
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
RU2276997C2 (ru) * 1999-08-30 2006-05-27 Санофи-Авентис Дойчланд Гмбх Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
US6821971B2 (en) * 2001-09-20 2004-11-23 The Procter & Gamble Company Fused pyrazolone compounds which inhibit the release of inflammatory cytokines
EP1443919A4 (en) * 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
AU2003219809A1 (en) 2002-02-14 2003-09-04 Myriad Genetics, Inc. Beta-sheet mimetics and composition and methods relating thereto
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
EP1906934A4 (en) * 2005-07-14 2012-03-07 Franco Folli DAILY DOSAGE SCHEME FOR THE TREATMENT OF DIABETES, OBESITY, METABOLIC SYNDROME AND POLYKYSTIC OVAIRE SYNDROME
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20090186817A1 (en) 2006-03-21 2009-07-23 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
EP2035450A2 (en) 2006-05-26 2009-03-18 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
US8198311B2 (en) 2006-11-01 2012-06-12 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2089389A2 (en) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2334671A1 (en) 2008-06-24 2011-06-22 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HRP20240805T1 (hr) 2013-06-05 2024-09-27 Bausch Health Ireland Limited Ultra-pročišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i uporabe
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN106674228B (zh) * 2016-12-09 2018-12-04 河南农业大学 多元杂环化合物及其制备方法和用途
JP7506832B2 (ja) * 2021-06-25 2024-06-26 株式会社日立産機システム 劣化診断装置および劣化診断方法、並びに電動機制御装置

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3334095A (en) * 1965-02-16 1967-08-01 Sandoz Ag Novel pyrrolo-oxazines and pyrrolo-oxazoles
US3334091A (en) * 1965-03-25 1967-08-01 Sandoz Ag Sedatives
GB1525845A (en) * 1976-07-30 1978-09-20 Ucb Sa 1,2,4,5-tetrahydro-3h-2-benzazepin-3-ones
IE50839B1 (en) * 1980-02-26 1986-07-23 Wyeth John & Brother Ltd Novel processes for preparing proline derivatives and analogous compounds
EP0042100A1 (de) * 1980-06-13 1981-12-23 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel
US4320057A (en) * 1980-06-23 1982-03-16 American Home Products Corporation Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
US4415496A (en) * 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
ZA833214B (en) * 1982-05-12 1983-12-28 Hoffmann La Roche Bicyclic compounds
US4552889A (en) * 1983-06-09 1985-11-12 Eli Lilly And Company 3-Mercaptomethyl-2-oxo-1-pyrrolidine acetic acids and use for hypertension
US4692438A (en) * 1984-08-24 1987-09-08 Hoffmann-La Roche Inc. Pyridazo-diazepines, diazocines, and -triazepines having anti-hypertensive activity
US4584294A (en) * 1984-11-07 1986-04-22 Merck & Co., Inc. Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents
EP0202046B1 (en) * 1985-04-30 1991-01-30 Eli Lilly And Company 7-substituted bicyclic pyrazolidinones
US4973585A (en) * 1986-06-13 1990-11-27 Merrell Dow Pharmaceuticals Tricyclic lactams active as antihypertensive agents
ZA874106B (en) * 1986-06-13 1987-12-08 Merrell Dow Pharmaceuticals Inc. Novel antihypertensive agent
ZA874107B (enExample) * 1986-06-13 1987-12-09
GB8629875D0 (en) * 1986-12-15 1987-01-28 Hoffmann La Roche Pyridazodiazepine derivatives
US4824832A (en) * 1987-12-30 1989-04-25 Merrell Dow Pharmaceuticals Inc. Sulfhydryl containing tricyclic lactams and their pharmacological methods of use
GB8926512D0 (en) * 1989-11-23 1990-01-10 Pfizer Ltd Therapeutic agents
AU7168091A (en) * 1989-12-22 1991-07-24 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5208230A (en) * 1990-12-21 1993-05-04 Merrell Dow Pharmaceuticals Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
EP0492369B1 (en) * 1990-12-21 1997-09-17 Merrell Pharmaceuticals Inc. Novel amino and nitro containing tricyclic compounds useful as inhibitors of ace
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
EP0533084A1 (en) * 1991-09-16 1993-03-24 Schering Corporation Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating and preventing myointimal proliferation

Also Published As

Publication number Publication date
HUT71099A (en) 1995-11-28
HU223663B1 (hu) 2004-11-29
EP0640086A1 (en) 1995-03-01
DE69325904D1 (de) 1999-09-09
NO944335L (no) 1995-01-13
NZ251930A (en) 1996-02-27
CA2133963A1 (en) 1993-11-25
AU4033293A (en) 1993-12-13
IL105680A0 (en) 1993-09-22
ATE182892T1 (de) 1999-08-15
KR100281450B1 (ko) 2001-02-01
MX9302824A (es) 1994-05-31
NO302573B1 (no) 1998-03-23
ES2138622T3 (es) 2000-01-16
JPH07506832A (ja) 1995-07-27
GR3031287T3 (en) 1999-12-31
DE69325904T2 (de) 1999-12-09
FI945363A0 (fi) 1994-11-14
CA2133963C (en) 1998-07-07
AU669364B2 (en) 1996-06-06
EP0640086B1 (en) 1999-08-04
KR950701634A (ko) 1995-04-28
IL105680A (en) 1998-01-04
DK0640086T3 (da) 1999-12-06
WO1993023403A1 (en) 1993-11-25
FI945363L (fi) 1994-11-14
JP3360079B2 (ja) 2002-12-24
FI108230B (fi) 2001-12-14
NO944335D0 (no) 1994-11-14
US5366973A (en) 1994-11-22

Similar Documents

Publication Publication Date Title
TW270115B (enExample)
TW225534B (enExample)
TW327172B (en) Novel mercaptoacetylamide bicyclic lactam derivatives
HU9403323D0 (en) 4-mercaptioacetylamino-[2] benzazepinone(3) derivatives, and use as enkephalinase inhibitors
NZ244462A (en) Fused benzazepine derivatives and medicaments
AU4041293A (en) Phenylderivate as inhibitors of atp citrate lyase
GR3026222T3 (en) Novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
EP0813527A4 (en) 6-SUBSTITUTED PYRAZOLO (3,4-D) PYRIMIDIN-4-ONE, PREPARATIONS, METHOD AND USE THEREOF
MY111201A (en) New imidazopyridines
GR3036867T3 (en) Hydroxymethylimidazodiazepines and their esters
CA2173876A1 (en) Alkoxy alkyl carbamates from imidazo(1,2-a)pyridines
AU3708093A (en) Processes for the preparation of amylase inhibitor
PL322452A1 (en) 6-arylpyrasole [3,4-d]pyrimidin-4-ones, preparations containing such compounds and methods of mking use of them
ZA936059B (en) Novel 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
GB9320785D0 (en) Dibenzylheterocyclic or dibenzylcycloalkyl derivatives as inhibitors of hiv intergrase
CA2141563A1 (en) Novel 2-Substituted Indane-2-Mercaptoacetylamide Tricyclic Derivatives Useful as Inhibitors of Enkephalinase
AU3810093A (en) Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
EP0618222A3 (en) Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid.
AU7186094A (en) Antihypertensive tricyclic azepine derivatives useful as inhibitors of enkephalinase and ace
AU4450489A (en) The use of ethylenediaminetetraacetic acid as inhibitor of calcium/calmodulin-dependent protein kinase ii or of protein kinase c
ZA933260B (en) Novel mercaptoacetylamido pyridazo(1,2)pyridazine, pyrazolo(1,2)pyridazine, pyridazo(1,2-a)(1,2)diazepine and pyrazolo(1,2-a)(1,2)diazepine derivatives useful as inhibitors of enkephalinase and ACE
IL107242A0 (en) Derivatives of benzeneborinic acid, preparation thereof and use thereof as synthetic intermediates
TW340108B (en) 1,1-difluoro-1,4-dichlorobutane and process for its preparation
AU3502189A (en) Use of diazepinones
PL294762A1 (en) Method of obtaining novel ethyl estars of 2,3-dihydroimidazo(1,2-a)pyrimidine-6-carboxylic acid